Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M707412200 on December 5, 2007

J. Biol. Chem., Vol. 283, Issue 10, 6193-6200, March 7, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
283/10/6193    most recent
M707412200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Metcalfe, C.
Right arrow Articles by Moody, P. C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Metcalfe, C.
Right arrow Articles by Moody, P. C. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Tuberculosis Prodrug Isoniazid Bound to Activating Peroxidases*

Clive Metcalfe{ddagger}, Isabel K. Macdonald{ddagger}1, Emma J. Murphy{ddagger}, Katherine A. Brown§, Emma Lloyd Raven{ddagger}, and Peter C. E. Moody2

From the Departments of {ddagger}Chemistry and Biochemistry, University of Leicester, Lancaster Road, Leicester LE1 9HN and §Department of Life Sciences, Division of Cell and Molecular Biology, Centre for Molecular Microbiology and Infection, Imperial College, Exhibition Road, London SW7 2AZ, United Kingdom

Isoniazid (INH, isonicotinic acid hydrazine) is one of only two therapeutic agents effective in treating tuberculosis. This prodrug is activated by the heme enzyme catalase peroxidase (KatG) endogenous to Mycobacterium tuberculosis but the mechanism of activation is poorly understood, in part because the binding interaction has not been properly established. The class I peroxidases ascorbate peroxidase (APX) and cytochrome c peroxidase (CcP) have active site structures very similar to KatG and are also capable of activating isoniazid. We report here the first crystal structures of complexes of isoniazid bound to APX and CcP. These are the first structures of isoniazid bound to any activating enzymes. The structures show that isoniazid binds close to the {delta}-heme edge in both APX and CcP, although the precise binding orientation varies slightly in the two cases. A second binding site for INH is found in APX at the {gamma}-heme edge close to the established ascorbate binding site, indicating that the {gamma}-heme edge can also support the binding of aromatic substrates. We also show that in an active site mutant of soybean APX (W41A) INH can bind directly to the heme iron to become an inhibitor and in a different mode when the distal histidine is replaced by alanine (H42A). These structures provide the first unambiguous evidence for the location of the isoniazid binding site in the class I peroxidases and provide rationalization of isoniazid resistance in naturally occurring KatG mutant strains of M. tuberculosis.


Received for publication, September 4, 2007 , and in revised form, October 29, 2007.

The atomic coordinates and structure factors (codes 2V23, 2V2E, 2VCF, 2VCN, and 2VCS) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported by Biotechnology and Biological Sciences Research Council Grants BBC/0011841 (to E. L. R. and P. C. E. M.), 91/B19083 (to E. L. R.), and BBS/S/A/2004/12421 (to E. L. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Present address: The Edward Jenner Inst. for Vaccine Research, Compton, Newbury, Berkshire RG20 7NN, UK.

2 To whom correspondence should be addressed. Tel.: 44-116-229-7097; Fax: 44-116-229-7084; E-mail: peter.moody{at}le.ac.uk.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. Suarez, K. Ranguelova, J. P. M. Schelvis, and R. S. Magliozzo
Antibiotic Resistance in Mycobacterium tuberculosis: PEROXIDASE INTERMEDIATE BYPASS CAUSES POOR ISONIAZID ACTIVATION BY THE S315G MUTANT OF M. TUBERCULOSIS CATALASE-PEROXIDASE (KatG)
J. Biol. Chem., June 12, 2009; 284(24): 16146 - 16155.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Zhao, S. Yu, K. Ranguelova, J. Suarez, L. Metlitsky, J. P. M. Schelvis, and R. S. Magliozzo
Role of the Oxyferrous Heme Intermediate and Distal Side Adduct Radical in the Catalase Activity of Mycobacterium tuberculosis KatG Revealed by the W107F Mutant
J. Biol. Chem., March 13, 2009; 284(11): 7030 - 7037.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement